SEC Form 4 · accession 0000899243-16-032201
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard L Love
Officer — Interim CEO and President · Director
Period of report
Oct 20, 2016
Accepted (ET)
Oct 24, 2016 · 6:09 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.4087 | Oct 20, 2016 | A | 500,000 | A | — | Oct 20, 2026 | Common Stock | 500,000 | 500,000 | D |
| Employee Stock Option (Right to Buy)F2 | $0.4087 | Oct 20, 2016 | A | 500,000 | A | — | Oct 20, 2026 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1The option is scheduled to vest in six monthly installments following the grant date, subject to the reporting person's continued employment with the issuer through the applicable vesting date.
- F2The option is scheduled to vest in six monthly installments following the grant date, subject to the reporting person's continued employment with the issuer through the applicable vesting date, and provided that a specified performance objective is achieved prior to October 2, 2018.